MAP3K8 and liver disorder: Additionally, inhibition of Tpl2 has been a promising target for inflammatory diseases including inflammatory bowel disease, rheumatoid arthritis and liver disease [42–44], and Tpl2 inhibitors are among the ones to be tested in clinical trials [18].